Harmony Biosciences Files 8-K on Financial Condition

TL;DR

**Harmony Biosciences just dropped an 8-K on its financials, so keep an eye out for details.**

AI Summary

Harmony Biosciences Holdings, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing, under the Securities Exchange Act of 1934, indicates that the company is providing an update on its financial performance. For investors, this matters because it offers a timely glimpse into the company's health and operational efficiency, which can influence stock valuation and future investment decisions.

Why It Matters

This filing provides investors with current information on Harmony Biosciences' financial health, which is crucial for evaluating the company's performance and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial condition and does not inherently present new risks, but rather provides information for risk assessment.

Analyst Insight

A smart investor would monitor for the full financial results that this 8-K foreshadows, as the current filing only indicates an update on financial condition without providing specific numbers.

Key Players & Entities

• Harmony Biosciences Holdings, Inc. (company) — the registrant filing the 8-K
• January 8, 2024 (date) — date of earliest event reported and filing date
• 001-39450 (dollar_amount) — Commission File Number
• HRMY (company) — trading symbol for Harmony Biosciences
• The Nasdaq Global Market (company) — exchange where Harmony Biosciences' stock is registered

Forward-Looking Statements

• Harmony Biosciences will release more detailed financial results soon. (Harmony Biosciences Holdings, Inc.) — high confidence, target: Q1 2024

FAQ

Key Financial Figures

• $0.00001 — ) on which registered Common Stock, $0.00001 par value per share HRMY The Nasdaq

Filing Documents

• hrmy-20240108x8k.htm (8-K) — 44KB
• hrmy-20240108xex99d1.htm (EX-99.1) — 41KB
• hrmy-20240108x8k001.jpg (GRAPHIC) — 1KB
• hrmy-20240108xex99d1001.jpg (GRAPHIC) — 10KB
• 0001558370-24-000128.txt ( ) — 229KB
• hrmy-20240108.xsd (EX-101.SCH) — 3KB
• hrmy-20240108_lab.xml (EX-101.LAB) — 16KB
• hrmy-20240108_pre.xml (EX-101.PRE) — 10KB
• hrmy-20240108x8k_htm.xml (XML) — 5KB

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 8, 2024, Harmony Biosciences Holdings, Inc. (the "Company") issued a press release announcing its preliminary unaudited net product revenue for the fourth quarter and year ended December 31, 2023. In addition, the Company provided guidance related to 2024 net product revenue and disclosed the number of shares repurchased during the fourth quarter and year ended December 31, 2023. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. Note Regarding Forward-Looking Statements Certain statements in this Current Report on Form 8-K constitute "forward-looking statements" within the meaning of the federal securities laws. These statements are based on management's current opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results. These forward looking statements are only predictions, not historical fact, and involve certain risks and uncertainties, as well as assumptions. Actual results, levels of activity, performance, achievements and events could differ materially from those stated, anticipated or implied by such forward-looking statements. While the Company believes that its assumptions are reasonable, it is very difficult to predict the impact of known factors, and, of course, it is impossible to anticipate all factors that could affect actual results. There are many risks and uncertainties that could cause actual results to differ materially from the forward-looking statements made herein including the risks discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2022, which was filed with the Securities and Exchange Commission ("SEC,") on February 21, 2023, as well as other factors described from time to time in the Company's filings with the SEC. Such forward-looking statements are made on

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1* Press release issued by the Company, dated January 8, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). * This Exhibit is furnished herewith and will not be deemed "filed" for purposes of Section 18 of the Exchange Act or deemed to be incorporated by reference into any filing under the Exchange Act or the Securities Act except to the extent that Harmony Biosciences Holdings, Inc. specifically incorporates it by reference.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. HARMONY BIOSCIENCES HOLDINGS, INC. Date: January 8, 2024 By: /s/ Sandip Kapadia Sandip Kapadia Chief Financial Officer and Chief Administrative Officer

View Full Filing

View this 8-K filing on SEC EDGAR